Two heart-valve engines, one coverage test
- Q1 2026 sales grew 16.7% to about $1.65 billion, led by TAVR and TMTT.
- TAVR is still the main business, with $1.20 billion of Q1 2026 sales and 14.4% growth.
- TMTT is the faster engine, with $175.1 million of Q1 2026 sales and 51.9% growth.
- The Critical Care sale sharpened Edwards into a more focused structural-heart company.
- The biggest near-term question is Medicare coverage for TAVR in asymptomatic patients.
Growth is working, price still matters
Edwards is showing the growth pattern investors wanted to see. In Q1 2026, total sales rose 16.7%. TAVR, the large core valve business, grew 14.4%. TMTT, the newer mitral and tricuspid valve business, grew 51.9%. That supports the main bull case: Edwards can keep growing even while its biggest product line gets larger.
The company also has a clearer focus after selling Critical Care. Edwards is now more tied to structural heart disease, which means heart problems caused by valves and related parts of the heart. That focus can help sales teams, research spending, and acquisitions point in the same direction.
The bear case is not that the company is weak. It is that expectations are high. TAVR must keep growing from a large base, TMTT must turn new procedures into common practice, and investors still need to ask whether the stock price already assumes too much success.
The main 2026 event is the CMS national coverage decision for TAVR. CMS has proposed broader Medicare coverage for asymptomatic severe aortic stenosis, but with coverage tied to evidence development. The final rule is the key test because it will shape how fast this new patient group can turn into real volume.
Premium devices for heart specialists
Edwards makes money by selling advanced heart-valve devices to hospitals and heart teams. Many of its products are used in catheter-based procedures, where doctors thread a device through blood vessels instead of opening the chest. That can make treatment possible for older or higher-risk patients.
The model depends on clinical proof. Edwards spends to run trials, win approvals, gain reimbursement, and train physicians. When the evidence is strong, a device can become part of standard care and create years of repeat hospital demand.
This model can break if a new device is hard to use, reimbursement is narrow, or doctors do not change their habits. TMTT is the clearest example. It is growing fast, but mitral and tricuspid disease are harder markets to build than aortic stenosis was.
Acquisitions add more optionality. JenaValve adds a possible path in aortic regurgitation, and Endotronix adds a heart-failure sensor platform. These can expand the company, but they also add integration and spending risk.
Valves, repair systems, and new bets
TAVR, led by SAPIEN
This is Edwards' main business. It treats aortic stenosis, a narrowing of the heart's aortic valve, using a catheter-based replacement valve.
TMTT, including PASCAL and EVOQUE
This group treats mitral and tricuspid valve disease. Q1 2026 sales grew 51.9%, making it the clearest growth engine.
SAPIEN M3 mitral replacement
SAPIEN M3 adds a U.S. mitral replacement launch to the TMTT portfolio. The key test is whether hospitals adopt replacement in patients who are not good fits for repair.
Surgical Structural Heart
This includes surgical valves such as INSPIRIS, MITRIS, and KONECT. Q1 2026 sales grew 10.1%, better than a slow mature-device story would suggest.
Surgical LAAC
Edwards plans a late 2026 launch in left atrial appendage closure, a procedure meant to reduce stroke risk in some patients. The open question is how much revenue it can add in 2027.
JenaValve and Endotronix platforms
JenaValve brings aortic regurgitation technology, and Endotronix brings a heart-failure sensor. Both widen the future pipeline, but neither is the main current revenue base.
Q1 2026 sales mix
The mix below uses Edwards' Q1 2026 product sales: TAVR at $1.20 billion, TMTT at $175.1 million, and Surgical Structural Heart at $276.2 million. TAVR is still the largest piece, so a slowdown there would matter more than a small miss in newer lines.
What could go wrong
Medicare coverage comes with tight limits
High impact · Medium oddsThe TAVR expansion for asymptomatic patients depends on the CMS coverage process. CMS has proposed coverage with evidence development, which means patients may need to be in an approved study or registry for Medicare payment. If the final rule is narrow, the new patient pool could grow slower than bulls expect.
TAVR growth fades from a large base
High impact · Medium oddsTAVR produced $1.20 billion of Q1 2026 sales and grew 14.4%. That is strong, but it also sets a tougher bar for the rest of 2026. If the recent growth came mostly from better focus on severe aortic stenosis, not a new wave of asymptomatic patients, growth could cool before coverage changes help.
TMTT adoption takes longer than hoped
Medium impact · Medium oddsTMTT grew 51.9% in Q1 2026, but it is still much smaller than TAVR. New mitral and tricuspid procedures need physician training, patient selection, and reimbursement support. SAPIEN M3 can help, but the market still has to be built.
New acquisitions do not scale
Medium impact · Medium oddsJenaValve and Endotronix give Edwards more ways to grow. They also bring integration risk and added spending before large sales are proven. If trials, approvals, or launches slip, the deals could weigh on results.
Valuation leaves less room for error
Medium impact · Medium oddsEdwards is a high-quality medical device company with strong financial health, but the stock is not priced like a broken business. If growth slows or the CMS outcome disappoints, the market may not give much credit for long-term potential. This is why the story can be good while the stock still needs discipline.
In one breath
What does Edwards Lifesciences actually make?
Edwards makes heart-valve devices. Its best-known products replace or repair damaged valves, often through catheter procedures that are less invasive than open-heart surgery.
Why is TAVR so important to Edwards?
TAVR is the largest product group, with $1.20 billion of Q1 2026 sales. It treats aortic stenosis, and broader Medicare coverage for asymptomatic patients could expand the market.
What is TMTT?
TMTT stands for Transcatheter Mitral and Tricuspid Therapies. It includes devices such as PASCAL, EVOQUE, and SAPIEN M3 that treat other heart valves beyond the aortic valve.
What is the main 2026 catalyst for EW stock?
The main catalyst is the final CMS coverage decision for TAVR. A favorable rule could help turn the asymptomatic aortic stenosis label into real Medicare-covered procedures.